Finance

Lists
Why is ORCHPHARMA down 2,14%?
Dive Deeper
ORCHPHARMA:NSE
Orchid Pharma Ltd
925,00 INR
-2,14%
(-20,25) 1D
15-окт., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for ORCHPHARMA...
Open
945,25 INR
High
950,25 INR
Low
925,00 INR
Mkt. cap
55,39 млд
Avg. vol.
107,15 миң
Volume
42,56 миң
52-wk high
1 143,50 INR
52-wk low
480,00 INR
EPS
-0,88 INR
No. of employees
1 миң
Open
945,25 INR
High
950,25 INR
Low
925,00 INR
Mkt. cap
55,39 млд
Avg. vol.
107,15 миң
Volume
42,56 миң
52-wk high
1 143,50 INR
52-wk low
480,00 INR
EPS
-0,88 INR
No. of employees
1 миң
News stories
From web sources and news partners
Profile
Orchid Pharma Limited is an Indian pharmaceutical company based in Chennai. It was founded by Kailasam Raghavendra Rao on 1 July 1992. Orchid Pharma is the only pharma company in India to have discovered a New Drug Enmetazobactam which is now approved in United States, Europe and India. Wikipedia
About Orchid Pharma Ltd
CEO-
Employees1,17 миң
Founded1992
Headquarters-
SectorPharmaceutical industry
Last report
2026-ж., 21-авг.
Fiscal period
Q1 2027
0,54 INR / 3,60 INR
-85,00%miss
Revenue / Est. (INR)
3,04 млд / 2,30 млд
+31,96%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
1,94 млд
2,07 млд
6,59 млд
3,04 млд
Cost of goods sold
1,33 млд
1,43 млд
5,03 млд
2,04 млд
Cost of revenue
1,33 млд
1,43 млд
5,03 млд
2,04 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
248,51 млн
241,28 млн
502,27 млн
280,38 млн
Operating expense
713,95 млн
715,86 млн
1,40 млд
968,16 млн
Total operating expenses
2,04 млд
2,15 млд
6,43 млд
3,01 млд
Operating income
-103,77 млн
-74,65 млн
163,81 млн
30,51 млн
Other non operating income
107,74 млн
56,09 млн
-238,03 млн
18,28 млн
EBT including unusual items
-57,24 млн
-126,14 млн
131,94 млн
32,97 млн
EBT excluding unusual items
-57,24 млн
-55,01 млн
54,86 млн
32,97 млн
Income tax expense
-
-
17,00 миң
723,00 миң
Effective tax rate
-
-
0,01%
2,19%
Other operating expenses
376,43 млн
384,29 млн
419,31 млн
578,29 млн
Net income
-57,24 млн
-126,14 млн
131,92 млн
32,24 млн
Net profit margin
-2,96%
-6,09%
2,00%
1,06%
Earnings per share
-1,13
-1,08
4,58
0,54
Interest and investment income
-
-
101,25 млн
-
Interest expense
-37,32 млн
-31,78 млн
-
-22,30 млн
Net interest expenses
-37,32 млн
-31,78 млн
101,25 млн
-22,30 млн
Depreciation and amortization charges
89,01 млн
90,29 млн
166,61 млн
109,49 млн
EBITDA
-15,99 млн
10,45 млн
269,63 млн
119,14 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору